Varda Space Raised $250 Million at $1.6 Billion Valuation

The orbital manufacturing startup secured funding in September 2026 to scale its pharmaceutical production capsules.

Updated on Sept. 30, 2026 in Biotech

Isometric editorial illustration of a metallic orbital capsule in space, representing technical pharmaceutical production in microgravity. — Varda Space secured $250 million in Series D funding in September 2026 to scale its automated orbital pharmaceutical manufacturing operations. AI Illustration. Upload story photo >

Live Poll

Do you believe manufacturing medicines in space will lead to significant breakthroughs for the average person?

Varda Space closed a $250 million Series D funding round in September 2026, reaching a total valuation of $1.6 billion. The El Segundo-based company has deployed six uncrewed orbital missions since 2023 to manufacture pharmaceuticals in microgravity.

Why it matters

The capital injection allows Varda to scale operations as it shifts toward a business model balancing government research with commercial pharmaceutical production. By producing drugs in microgravity, the company aims to achieve levels of molecular efficiency and purity unattainable in Earth-based facilities.

Varda utilizes uncrewed capsules launched via SpaceX Falcon 9 rideshare missions, which reach re-entry speeds of 25 times the speed of sound. The firm currently manages a workforce of 275 employees.

The players

Varda Space

An orbital manufacturing startup that develops uncrewed capsules to produce pharmaceuticals in microgravity.

Lux Capital

A venture capital firm focused on deep-tech investments that led the Series D funding round.

Natural Capital

A venture firm that co-led the $250 million investment in Varda Space.

Mikael Dolsten

A life sciences leader and board member who joined the company in August 2026.

The details

Varda manufactures pharmaceuticals by leveraging microgravity, an environment where the lack of buoyancy-driven convection allows for superior crystal growth and chemical uniformity. The company uses specialized uncrewed capsules that act as automated labs in orbit, which are later recovered after re-entering the atmosphere. This process allows for the production of drug formulations with higher purity levels than those produced under Earth's gravity-influenced manufacturing conditions.

2021: Varda Space was founded.
2023: The company began deploying its orbital missions.
August 2026: Mikael Dolsten was appointed to the company board.
September 2026: The Series D funding round closed.
2030: Debut of the company's next-generation capsule.

Space
Sept. 18
SpaceX Raised $75 Billion in June 2026 IPO
Space
Sept. 18
NASA Awarded SpaceX $946 Million for New Crewed Missions
Space
Sept. 29
SpaceX Starship Reached Orbit Despite Engine Failure

The Tech Race

Varda Space operates as a downstream beneficiary of the launch cadence and cost-per-kilogram improvements established by the SpaceX Falcon 9 platform. The company is now pivoting its competitive focus from initial R&D to a projected commercial shift by 2032.

The company’s growth indicates a long-term trajectory toward higher-purity specialized medications manufactured in space rather than on the ground. Customers and healthcare providers should monitor the 2030 deployment of next-generation capsules as a signal of expanded production capacity.

The takeaway

Varda's latest round signals growing investor confidence in the commercial viability of space-based pharmaceutical manufacturing. Observers should track the 2030 launch of the next-generation capsule as the critical milestone for scaling beyond government-funded research payloads.